CHEMOPREVENTION WITH AEROSOLIZED LET-7 MICRORNA IN MOUSE MODELS OF NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA)
CHEMOPREVENTION WITH AEROSOLIZED LET-7 MICRORNA IN MOUSE MODELS OF NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA)
批准号:
10020543
负责人:
CHINTHALAPALLY RAO
金额:
$84.94万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-28 至 2022-02-27
关键词:
A/J MouseAdenocarcinomaAdenocarcinoma CellBenzo(a)pyreneCCND2 geneCDC25A geneCell Cycle ProgressionCellsChemopreventionChemopreventive AgentContractorDevelopmentDoseDrug KineticsExperimental ModelsFamilyFormulationGene ExpressionGenesHMGA2 geneHistologicHumanImmuneInfiltrationLungLung AdenocarcinomaLung AdenomaLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMapsMicroRNAsModelingMusNon-Small-Cell Lung CarcinomaOncogenesPharmacodynamicsPolymerase Chain ReactionRegulator GenesReportingReverse TranscriptionSmall RNASquamous cell carcinomaTranscription Repressor/CorepressorTumor SubtypeTumor Suppressor ProteinsUntranslated RNAWild Type Mouseaerosolizedbaseimmune checkpointlung carcinogenesismimeticsmouse modelnanonoveloverexpressionside effect
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The aim of the proposed study is to evaluate the efficacy of a novel chemopreventive strategy based on the delivery of microRNA mimetics in experimental models of lung carcinogenesis in mice. MicroRNAs are noncoding small RNAs acting as post-transcriptional repressors and regulators of gene expression. MicroRNAs are grossly dysregulated in human cancers, including lung cancer. The microRNAs that are under-expressed in cancer can be functionally classified as tumor-suppressors while those that are over-expressed act as oncogenes. The let-7 microRNA family is a well characterized family of tumor suppressors whose genes map to different chromosomal regions that are frequently deleted in lung cancer. Let-7 microRNAs negatively regulate multiple oncogenes including RAS, MYC, and HMGA2, as well as cell-cycle progression regulator genes such as CDC25A, CDK6, and cyclin D2. Recent results have reported on the development of an aerosolized let-7B mimetic that inhibited benzo[a]pyrene-induced lung adenoma volume by 72% in A/J mice (Nano Lett., 19: 2231-2242, 2019), although mice in this model rarely develop adenocarcinomas. As lung adenocarcinomas and squamous cell carcinomas account for ~80% of all human cancer histological subtypes, the objectives of this Task Order are to determine 1) if aerosolized let-7b will be effective against the two most common lung tumor subtypes, and 2) if aerosolized delivery of let-7b to the lungs could minimize potential systemic side effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod
-
批准号:10927554
-
项目类别:
-
资助金额:$114.04万
-
财政年份:2023
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
-
批准号:10677989
-
项目类别:
-
资助金额:$104.61万
-
财政年份:2022
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT
-
批准号:10705393
-
项目类别:
-
资助金额:$98.23万
-
财政年份:2022
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERSTASK ORDER TITLE: PREVENTING FAP-CRC USING
-
批准号:10652736
-
项目类别:
-
资助金额:$14.33万
-
财政年份:2022
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER
-
批准号:10503245
-
项目类别:
-
资助金额:$48.25万
-
财政年份:2021
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER
-
批准号:10678625
-
项目类别:
-
资助金额:$63.1万
-
财政年份:2021
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
PREVENT EFFICACY POOL: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM
-
批准号:10411703
-
项目类别:
-
资助金额:$91.15万
-
财政年份:2021
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
TASK ORDER TITLE: PREVENTING COLORECTAL CANCER USING TRAIL-INDUCING ONC201 ALONE OR IN COMBINATION WITH NSAID
-
批准号:10269144
-
项目类别:
-
资助金额:$87.95万
-
财政年份:2020
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
IGF::OT::IGF PROSTATE CANCER PREVENTION BY ASPIRIN AND/OR OTHER NSAIDS TORFP 2016-E03HHSN2612015000381PERIOD OF PERFORMANCE: 07/07/2016 - 03/06/2019
-
批准号:9360885
-
项目类别:
-
资助金额:$62.51万
-
财政年份:2016
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
IGF::OT::IGF PREVENT EFFICACY: OPTIMIZATION OF GEM MODELS FOR HIGH-RISK COHORTS OF HUMAN PANCREATIC CYSTADENOMAS, IPMNS, AND PANINS PROGRESSION TO PDAC.
-
批准号:9152469
-
项目类别:
-
资助金额:$59.94万
-
财政年份:2015
-
负责人:CHINTHALAPALLY RAO
-
依托单位:
HHSN261201200020I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Chemoprevention by Aerosolized Bexarotene in Mouse Models of All T
-
批准号:8945362
-
项目类别:
-
资助金额:$60.71万
-
财政年份:2014
-
负责人:CHINTHALAPALLY RAO
-
依托单位:--
Molecular Heterogeneity of Inflammation and Growth Factor Pathways in Sporadic and Syndromic Colon Cancers: Implications for Prevention and Therapeutic TrialsPOP: 09/15/2014-09/14/2015
-
批准号:8944482
-
项目类别:
-
资助金额:$48.2万
-
财政年份:2014
-
负责人:CHINTHALAPALLY RAO
-
依托单位:--
HHSN2612012000131/HHSN26100010Base Contract Title: Preclinical Efficacy and Intermediate Endpoint Biomarkers. Task Order Title: Preclinical Studies to Evaluate the Combination of Metformin and As
-
批准号:8947463
-
项目类别:
-
资助金额:$53.09万
-
财政年份:2014
-
负责人:CHINTHALAPALLY RAO
-
依托单位:--
Multi-Antigen Vaccine for Lung Cancer PreventionPOP: 09/18/2014-09/17/2016
-
批准号:8941097
-
项目类别:
-
资助金额:$88.45万
-
财政年份:2014
-
负责人:CHINTHALAPALLY RAO
-
依托单位:--
HHSN2612012000201/HHSN26100006 Title: Preclinical In Vitro And In Vivo Screening Assays For Cancer Preventative Reagent Development, Project: Targeting CCK2R for Pancreatic Cancer Prevention
-
批准号:8944735
-
项目类别:
-
资助金额:$47.46万
-
财政年份:2014
-
负责人:CHINTHALAPALLY RAO
-
依托单位:--
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
-
批准号:30840003
-
项目类别:专项基金项目
-
资助金额:12.0万元
-
批准年份:2008
-
负责人:焦宇飞
-
依托单位: